Probiotics and conventional terapy: New fronter in therapeutic approach in articular manifestations of IBD;Probiotici e terapia convenzionale: Nuove frontiere nella gestione delle manifestazioni articolari delle malattie infiammatorie intestinali (IBD)

Progress in Nutrition

Volumn 16, Issue 3, 2014, Pages 176-187

  Tomasello, Giovanni ^a,c   Palumbo, Vincenzo Davide ^a,c   Miceli, Angelo ^a   Sinagra, Emanuele ^a,b,c   Bruno, Antonio ^a,c   Abruzzo, Alida ^a   Cappello, Francesco ^c,f   Patti, Angelo Maria ^c,f   Giglio, Rosaria Maria ^c,f   Damiani, Provvidenza ^a,c   Tomasello, Riccardo ^a   Noto, Marcello ^d   Arculeo, Vincenza Maria ^a   Accardo, Maurizio Filippo ^e   Lo Monte, Attilio Ignazio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Oncology Unit   (Italy)

^c Euro Mediterranean Institute of Science and Technology (IEMEST)   (Italy)

^d AOUP Paolo Giaccone   (Italy)

^e KORE UNIVERSITY OF ENNA   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

Author keywords

Articular manifestation due to IBD; Extraintestinal manifestations of IBD; Gut microflora; IBD; Intestinal bowel diseases; Microbiota; Probiotics

Indexed keywords

C REACTIVE PROTEIN; DICLOFENAC; MESALAZINE; PROBIOTIC AGENT;

ARTHROPATHY; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL LABORATORY; CLINICAL TRIAL (TOPIC); COLON MUCOSA; CONSULTATION; CROHN DISEASE; DISEASE ACTIVITY; ENDOSCOPY; ENTEROCOCCUS FAECIUM; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS SALIVARIUS; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; SACCHAROMYCES; TABLET; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; WESTERN ONTARIO MCMASTER SCORE;

ENTEROCOCCUS FAECIUM; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS SALIVARIUS; SACCHAROMYCES;

EID: 84922656174     PISSN: 11298723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.
2. Farmer RG, Michener WM (1980) Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol 9:271.277.
3. Yang H, McElree C (1993) Familial empirical risks for inflammatory bowel disease: difference between Jews and non-Jews. Gut 34:517-524.
4. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841-1854.
5. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut. 1995;37:668-673.
6. Kaplan GG, Jackson T, Sands BE, Frisch M, Andersson RE, Korzenik J. The risk of developing Crohn's disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008;103:2925-2931.
7. Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB. Nutritional modulation of the inflammatory response in inflammatory bowel disease - from the molecular to the integrative to the clinical. World J Gastroenterol. 2007;13:1-7.
8. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn's disease. Scand J Gastroenterol. 2008;43:961-966.
9. Soderholm JD, Yang P-C, Ceponis P, et al. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002;123:1099-1108.
10. Bull TJ, McMinn EJ, Sidi-Boumedine K, et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J Clin Microbiol. 2003;41:2915-2923.
11. Marineaţə A, Rezuş E, Mihai C, Prelipcean CC. Extra intestinal manifestations and complications in inflammatory bowel disease. Rev Med Chir Soc Med Nat Iasi 2014;118:279-88.
12. Rath H C, Herfarth H H, Ikeda J S, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human 02 microglobulin transgenic rats. J Clii Invest 1996: 98: 945-53.
13. Rath HC, Schultz M, Freitag R, Dieleman LA, Li F, Linde HJ, Schölmerich J, Sartor RB. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun. 2001;69:2277-2285.
14. Kim N, Kunisawa J, Kweon Mn et al., Oral feeding of Bifidobacterium bifidum (BGN4) prevent CD4(+) CD45Rb (high) T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin J Immunol 2007 April; 123(1):30-9.
15. Ouwehand A.C, Salminem S, Roberts Pj, et al., Disease-Dependent adhesion of lactic acid bacteria to the human intestinal mucosa. Clin Diagn Lab Immunol 2003 July; 10(4):643-646.
16. Mach T, Clinical Usefulness of probiotics in inflammatory bowel diseases. Journal of Physiologi 2006, 57; Suppl 9:23-33.
17. Schwartz M, Cohen R, Optimizing conventional terapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008 Dec;10(6):585-90.
18. Rioux Kp, Fedorak RN, Probiotics in the treatment of inflammatory bowel disease. J Clinic Gastroenterol. 2006; 40:260-63.
19. Nigel Yeoh, Jeremy P. Burton, Praema Suppiah, Gregor Reid, Simon Stebbings The Role of the Microbiome in Rheumatic Diseases. Current Rheumatology Reports February 2013, 15:314.
20. Karimi O, Peña AS. Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. Rev Esp Enferm Dig 2005;97:570-4.
21. Sinagra E, Tomasello G, Raimondo D, et al. Nutrition, malnutrition and dietary interventions in inflammatory bowel disease. Progr Nutr 2014; 16 (2): 79-89
22. Bellavia M, Rappa F, Lo Bello M, et al. Lactobacillus casei and bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice. J Biol Regul Homeost Agents 2014 Apr-Jun;28(2):251-61.
23. Tralongo P, Tomasello G, Sinagra E, et al. The role of butyric acid as a oprotective agent against inflammatory bowel disease. Euromediterranean Biomedical Journal 2014; 9(4), 24-35
24. Sinagra E, Tomasello G, Cappello F, et al. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents. 2013 Oct-Dec;27(4):919-33.
25. Bellavia M, Tomasello G, Romeo M, et al. Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microbiol Immunol. 2013 Dec;202(6):393-406. doi: 10.1007/s00430-013-0305-2. Epub 2013 Jul 18. Review.
26. Tomasello G, Bellavia M, Damiano G, Gioviale MC, Lo Monte AI. Possible relation between gut microflora composition and oncogenic risk: is stimulation of inflammation the one ring of connection? Reviews in Medical Microbiology 2012; 23: 52-57.